COL18A1 and breast carcinoma: Sun et al. also reported that the tumor-inhibiting effect of the paclitaxel-cisplatin (TP) regimen combined with recombinant human endostatin on breast cancer is better than that of the TP regimen alone in xenograft-bearing nude mice [6].